In vitro and in vivo small intestinal metabolism of CYP3A and UGT substrates in preclinical animals species and humans: Species differences

Drug Metabolism Reviews

Volumn 43, Issue 4, 2011, Pages 476-498

  Komura, Hiroshi ^a   Iwaki, Masahiro ^b  

^a JAPAN TOBACCO INC   (Japan)

^b KINKI UNIVERSITY   (Japan)

Author keywords

Drug metabolizing activity; Efflux transporter; First pass effect; Human; Intestinal availability; Monkey; MRNA

Indexed keywords

BAICALEIN; BUFURALOL; BUPRENORPHINE; CYCLOSPORIN; CYTOCHROME P450 3A; CYTOCHROME P450 3A12; CYTOCHROME P450 3A13; CYTOCHROME P450 3A4; CYTOCHROME P450 3A8; CYTOCHROME P450 3A9; DEXTROMETHORPHAN; DICLOFENAC; GLUCURONOSYLTRANSFERASE; GLUCURONOSYLTRANSFERASE 1A10; GLUCURONOSYLTRANSFERASE 1A7; GLUCURONOSYLTRANSFERASE 1A8; KETOCONAZOLE; MESSENGER RNA; MIDAZOLAM; NIFEDIPINE; NISOLDIPINE; RALOXIFENE; RAPAMYCIN; SILDENAFIL; TACROLIMUS; TESTOSTERONE; TROLEANDOMYCIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VARDENAFIL; VERAPAMIL;

DOG; DRUG BIOAVAILABILITY; DRUG HYDROXYLATION; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME KINETICS; ENZYME MECHANISM; ENZYME SUBSTRATE; FIRST PASS EFFECT; GENE EXPRESSION PROFILING; HAPLORHINI; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MICROSOME; NONHUMAN; PROTEIN EXPRESSION; REVIEW; SMALL INTESTINE; SPECIES DIFFERENCE;

ANIMALS; CYTOCHROME P-450 CYP3A; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GLUCURONOSYLTRANSFERASE; HUMANS; INTESTINES; PHARMACOKINETICS; SPECIES SPECIFICITY; SUBSTRATE SPECIFICITY;

EID: 80054948359     PISSN: 03602532     EISSN: 10979883     Source Type: Journal    
DOI: 10.3109/03602532.2011.597401     Document Type: Review

References (171)

1. Abdallah, C., Besner, J. G., du Souich, P. (1995). Presystemic elimination of morphine in anesthetized rabbits: contribution of the intestine, liver, and lungs. Drug Metab Dispos 23:584-589.
2. Aiba, T., Takehara, Y., Okuno, M., Hashimoto, Y. (2003). Poor correlation between intestinal and hepatic metabolic rates of CYP3A4 substrates in rats. Pharm Res 20:745-748. (Pubitemid 36515306)
3. Akabane, T., Tabata, K., Kadono, K., Sakuda, S., Terashita, S., Teramura, T. (2010). A comparison of pharmacokinetics between humans and monkeys. Drug Metab Dispos 38:308-316.
4. Arellano, C., Philibert, C., Vachoux, C., Woodley, J., Houin, G. (2007). Te metabolism of midazolam and comparison with other CYP enzyme substrates during intestinal absorption: in vitro studies with rat everted gut sacs. J Pharm Pharmaceut Sci 10:26-36. (Pubitemid 46647804)
5. Bae, S. K., Chung, W. S., Kim, E. J., Rhee, J. K., Kwon, J. W., Kim, W. B., et al. (2004). Pharmacokinetics of DA-7867, a new oxazolidione, after intravenous or oral administration to rats: intestinal frst-pass efect. Antimicrob Agents Chemother 48:659-662. (Pubitemid 38141739)
6. Bae, S. K., Yang, K. H., Aryal, D. K., Kim, Y. G., Lee, M. G. (2009). Pharmacokinetics of amitriptyline and one of its metabolites, nortriptyline, in rats: little contribution of considerable hepatic frst-pass efect to low bioavailability of amitriptyline due to great intestinal frst-pass efect. J Pharm Sci 98:1587-1601.
7. Bernard, O., Guillemette, C. (2004). Te main role of UGT1A9 in the hepatic metabolism of mycophenolic acid and the efects of naturally occurring variants. Drug Metab Dispos 32:775-778. (Pubitemid 38955603)
8. Bowalgaha, K., Miners, J. O. (2001). Te glucuronidation of mycophenolic acid by human liver, kidney, and jejunum microsomes. Br J Clin Pharmacol 52:605-609.
9. Boxenbaum, H. (1980). Interspecies variation in liver weight, hepatic blood fow, and antipyrine intrinsic clearance: extrapolation of data to benzodiazepines and phenytoin. J Pharmacokinet Biopharm 8:165-176. (Pubitemid 10003349)
10. Brand, W., Boersma, M. G., Bik, H., Hoek-van den Hil, E. F., Vervoort, J., Barron, D., et al. (2010). Phase II metabolism of hesperetin by individual UDP-glucuronosyltransferases and sulfotransferases and rat and human tissue samples. Drug Metab Dispos 38:617-625.
11. Brand, W., van der Wel, P. A., Rein, M. J., Barron, D., Williamson, G., van Bladeren, P. J., et al. (2008). Metabolism and transport of the citrus favonoid hesperetin in Caco-2 cell monolayers. Drug Metab Dispos 36:1794-1802.
12. Carr, B., Norcross, R., Fang, Y., Lu, P., Rodrigues, A. D., Shou, M., Rushmore, T., et al. (2006). Characterization of the rhesus monkey CYP3A64 enzyme: species comparisons of CYP3A substrate specifcity and kinetics using baculovirus-expressed recombinant enzymes. Drug Metab Dispos 34:1703-1712. (Pubitemid 44427473)
13. Chen, X., Yin, O. Q., Zuo, Z., Chow, M. S. (2005). Pharmacokinetics and modeling of quercetin and metabolites. Pharm Res 22:892-901. (Pubitemid 40898099)
14. Choi, Y. H., Kim, S. G., Lee, M. G. (2006). Dose-independent pharmacokinetics of metformin in rats: hepatic and gastrointestinal frst-pass efects. J Pharm Sci 95:2543-2552. (Pubitemid 44726394)
15. Crespy, V., Morand, C., Manach, C., Besson, C., Demigne, C., Remesy, C. (1999). Part of quercetin absorbed in the small intestine is conjugated and further secreted in the intestinal lumen. Am J Physiol 277:G120-G126 (Pubitemid 29352652)
16. Crowe, A., Bruelisauer, A., Duerr, L., Guntz, P., Lemaire, M. (1999). Absorption and intestinal metabolism of SDZ-RAD and rapamycin in rats. Drug Metab Dispos 27:627-632. (Pubitemid 29214476)
17. Cubitt, H. E., Houston, J. B., Galetin, A. (2009). Relative importance of intestinal and hepatic glucuronidation-Impact on the prediction of drug clearance. Pharm Res 26:1073-1083.
18. de Graaf, I. A., de Kanter, R., de Jager, M. H., Camacho, R., Langenkamp, E., van de Kerkhof, E. G., et al. (2006). Empirical validation of a rat in vitro organ slice model as a tool for in vivo clearance prediction. Drug Metab Dispos 34;591-599.
19. de Kanter, R., Tuin, A., van de Kerkhof, E., Martignoni, M., Draaisma, A. L., de Jager, M. H., et al. (2005). A new technique for preparing precision-cut slices from small intestine and colon for drug biotransformation studies. J Pharmacol Toxicol Meth 51:65-72. (Pubitemid 41556705)
20. Dean, B. J., Chang, S., Elipe, M. V., Xia, Y. Q., Braun, M., Soli, E., et al. (2007). Metabolism of MK-0524, a prostaglandin D2 Receptor 1 antagonist, in microsomes and hepatocytes from preclinical species and humans. Drug Metab Dispos 35:283-292. (Pubitemid 46148742)
21. Doherty MM, Pang KS. (2000). Route-dependent metabolism of morphine in the vascularly perfused rat small intestine preparation. Pharm Res 17:291-298. (Pubitemid 30225132)
22. Dubey, R. K., Singh, J. (1988). Localization and characterization of drug-metabolizing enzymes along the villus-crypt surface of the rat small intestine-II. Conjugases. Biochem Pharmacol 37:177-184. (Pubitemid 18039700)
23. Ducharme, M. P., Warbasse, L. H., Edwards, D. J. (1995). Disposition of intravenous and oral cyclosporine after administration with grapefruit juice. Clin Pharmacol Ter 57:485-491.
24. Eeckhoudt, S. L., Horsmans, Y., Verbeeck, R. K. (2002). Diferential induction of midazolam metabolism in the small intestine and liver by oral and intravenous dexamethasone pretreatment in rat. Xenobiotica 32:975-984. (Pubitemid 35347005)
25. Emoto, C., Yamazaki, H., Iketaki, H., Yamasaki, S., Satoh, T., Shimizu, R., et al. (2001). Cooperativity of α-naphthofavone in cytochrome P450 3A-dependent drug oxidation activities in hepatic and intestinal microsomes from mouse and human. Xenobiotica 31:265-275. (Pubitemid 32643307)
26. Emoto, C., Yamazaki, H., Yamasaki, S., Shimada, N., Nakajima, M., Yokoi, T. (2000a). Characterization of cytochrome P450 enzymes involved in drug oxidations in mouse intestinal microsomes. Xenobiotica 30:943-953.
27. Emoto, C., Yamazaki, H., Yamasaki, S., Shimada, N., Nakajima, M., Yokoi, T. (2000b). Use of everted sacs of mouse small intestine as enzyme sources for the study of drug oxidation activities in vitro. Xenobiotica 30:971-982.
28. Fisher, M. B., Campanale, K., Ackermann, B. L., Vandenbranden, M., Wrighton, S. A. (2000). In vitro glucuronidation using human liver microsomes and the pore-forming peptide alamethicin. Drug Metab Dispos 28:560-566. (Pubitemid 30238515)
29. Fisher, M. B., Paine, M. F., Strelevitz, T. J., Wrighton, S. A. (2001). Te role of hepatic and extrahepatic UDP-glucuronosyltransferases in human drug metabolism. Drug Metab Rev 33:273-297. (Pubitemid 33136266)
30. Fisher, M. B., Vandenbranden, M., Findlay, K., Burchell, B., Tummel, K. E., Hall, S. D., et al. (2000). Tissue distribution and interindividual variation in human UDP-glucuronosyltransferase activity: relationship between UGT1A1 promoter genotype and variability in a liver bank. Pharmacogenetics 10:727-739.
31. Floren, L. C., Bekersky, I., Benet, L. Z., Mekki, Q., Dressler, D., Lee, J. W., et al. (1997). Tacrolimus oral bioavailability doubles with coadministration of ketoconazole. Clin Pharmacol Ter 62:41-49. (Pubitemid 27327098)
32. Fraser, D. J., Feyereisen, R., Harlow, G. R., Halpert, J. R. (1997). Isolation, heterologous expression, and functional characterization of a novel cytochrome P450 3A enzyme from a canine liver cDNA library. J Pharmacol Exp Ter 283:1425-1432. (Pubitemid 28016518)
33. Fromm, M. F., Busse, D., Kroemer, H. K., Eichelbaum, M. (1996). Diferential induction of prehepatic and hepatic metabolism of verapamil by rifampin. Hepatology 24:796-801. (Pubitemid 26334275)
34. Fujiwara, R., Nakajima, M., Oda, S., Yamanaka, H., Ikushiro, S., Sakaki, T., et al. (2010). Interactions between human UDP-glucuronosyltransferase (UGT) 2B7 and UGT1A enzymes. J Pharm Sci 99:442-454.
35. Fujiwara, R., Nakajima, M., Yamanaka, H., Nakamura, A., Katoh, M., Ikushiro, S., et al. (2007a). Efects of coexpression of UGT1A9 on enzymatic activities of human UGT1A isoforms. Drug Metab Dispos 35:747-757. (Pubitemid 46641545)
36. Fujiwara, R., Nakajima, M., Yamanaka, H., Katoh, M., Yokoi, T. (2007b). Interactions between human UGT1A1, UGT1A4, and UGT1A6 afect their enzymatic activities. Drug Metab Dispos 35:1782-1787.
37. Galetin, A., Houston, J. B. (2006). Intestinal and hepatic metabolic activity of fve cytochrome P450 enzymes: impact on prediction of frst-pass metabolism. J Pharmacol Exp Ter 318:1220-1229. (Pubitemid 44268329)
38. Gertz, M., Davis, J. D., Harrison, A., Houston, J. B., Galetin, A. (2008). Grapefruit juice-drug interaction studies as a method to assess the extent of intestinal availability: utility and limitations. Curr Drug Metab 9;785-795.
39. Ghosal, A., Hapangama, N., Yuan, Y., Achanfuo-Yeboah, J., Iannucci, R., Chowdhury, S., et al. (2004). Identifcation of human UDP-glucuronosyltransferase enzyme(s) responsible for the glucuronidation of ezetimibe (Zetia). Drug Metab Dispos 32:314-320. (Pubitemid 38263889)
40. Glaeser, H., Drescher, S., Hofmann, U., Heinkele, G., Somogyi, A. A., Eichelbaum, M., et al. (2004). Impact of concentration and rate of intraluminal drug delivery on absorption and gut wall metabolism of verapamil in humans. Clin Pharmacol Ter 76:230-238. (Pubitemid 39221797)
41. Gomez, D. Y., Wacher, V. J., Tomlanovich, S. J., Herbert, M. F., Benet, L. Z. (1995). Te efects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine. Clin Pharmacol Ter 58:15-19.
42. Gong, Q. H., Cho, J. W., Huang, T., Potter, C., Gholami, N., Basu, N. K., et al. (2001). Tirteen UDP glucuronosyltransferase genes are encoded at the human UGT1 gene complex locus. Pharmacogenetics 11:357-368. (Pubitemid 32537410)
43. Gorski, J. C., Vannaprasaht, S., Hamman, M. A., Ambrosius, W. T., Bruce, M. A., Haehner-Daniels, B., et al. (2003). Te efect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity. Clin Pharmacol Ter 74:275-287. (Pubitemid 37083103)
44. Granvil, C. P., Yu, A. M., Elizondo, G., Akiyama, T. E., Cheung, C., Feigenbaum, L., et al. (2003). Expression of the human CYP3A4 gene in the small intestine of transgenic mice: in vitro metabolism and pharmacokinetics of midazolam. Drug Metab Dispos 31:548-558. (Pubitemid 36444163)
45. Gregory, P. A., Lewinsky, R. H., Gardner-Stephen, D. A., Mackenzie, P. I. (2004). Regulation of UDP glucuronosyltransferases in the gastrointestinal tract. Toxicol App Pharmacol 199;354-363. (Pubitemid 39208734)
46. Guengerich, F. P., Martin, M. V., Beaune, P. H., Kremers, P., Wolf, T., Waxman, D. J. (1986). Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism. J Biol Chem 261:5051-5060. (Pubitemid 17204301)
47. Gupta, S. K., Bakran, A., Johnson, R. W., Rowland, M. (1988). Erythromycin enhances the absorption of cyclosporin. Br J Clin Pharmacol 25:401-402.
48. Gupta, M., Kovar, A., Meibohm, B. (2005). Te clinical pharmacokinetics of phosphodiesterase-5 inhibitors for erectile dysfunction. J Clin Pharmacol 45:987-1003. (Pubitemid 41192358)
49. Hanada, K., Ikemi, Y., Kukita, K., Mihara, K., Ogata, H. (2008). Stereoselective frst-pass metabolism of verapamil in the small intestine and liver in rats. Drug Metab Dispos 36:2037-2042.
50. Hashimoto, Y., Sasa, H., Shimomura, M., Inui, K. (1998). Efects of intestinal and hepatic metabolism on the bioavailability of tacrolimus in rats. Pharm Res 15:1609-1613. (Pubitemid 28465749)
51. Hebert, M. F., Roberts, J. P., Prueksaritanont, T., Benet, L. Z. (1992). Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction. Clin Pharmacol Ter 52:453-457.
52. Higashikawa, F., Murakami, T., Kaneda, T., Kato, A., Takano, M. (1998). Dose-dependent intestinal and hepatic frst-pass metabolism of midazolam, a cytochrome P450 3A substrate with diferently modulated enzyme activity in rats. J Pharm Pharmacol 51:67-72. (Pubitemid 29097271)
53. Hirunpanich, V., Katagi, J., Sethabouppha, B., Sato, H. (2006). Demonstration of docosahexaenoic acid as a bioavailability enhancer for CYP3A substrates: in vitro and in vivo evidence using cyclosporin in rats. Drug Metab Dispos 34:305-310. (Pubitemid 43145032)
54. Hirunpanich, V., Murakoso, K., Sato, H. (2008). Inhibitory efect of docosahexaenoic acid (DHA) on the intestinal metabolism of midazolam: in vitro and in vivo studies in rats. Int J Pharm 351:133-143.
55. Ho, Y. F., Huang, D. K., Hsueh, W. C., Lai, M. Y., Yu, H. Y., Tsai, T. H. (2009). Efect of St. John's wort extract on indinavir pharmacokinetics in rats: diferentiation of intestinal and hepatic impacts. Life Sci 85:296-302.
56. Holtbecker, N., Fromm, M. F., Kroemer, H. K., Ohnhaus, E. E., Heidemann, H. (1996). Te nifedipine-rifampin interaction. Evidence for induction of gut wall metabolism. Drug Metab Dispos 24:1121-1123. (Pubitemid 26346226)
57. Houston, J. B., Kenworthy, K. E. (2000). In vitro-in vivo scaling of CYP kinetic data not consistent with the classical Michaelis-Menten model. Drug Metab Dispos 28:246-254. (Pubitemid 30137047)
58. Ikemura, K., Urano, K., Matsuda, H., Mizutani, H., Iwamoto, T., Okuda, M. (2009). Decreased oral absorption of cyclosporine A after liver ischemia-reperfusion injury in rats: the contribution of CYP3A and P-glycoprotein to the frst-pass metabolism in intestinal epithelial cells. J Pharmacol Exp Ter 328:249-255.
59. Itääho, K., Court, M. H., Uutela, P., Kostiainen, R., Radominska-Pandya, A., Finel, M. (2009). Dopamine is a low-afnity and high-specifcity substrate for the human UDP-glucuronosyltransferease 1A10. Drug Metab Dispos 37:768-775.
60. Iwamoto, K., Klaassen, C. D. (1977). First-pass efect of morphine in rats. J Pharmacol Exp Ter 200:236-244.
61. Iwao, T., Inoue, K., Hayashi, Y., Yuasa, H., Watanabe, J. (2002). Metabolic extraction of nifedipine during absorption from the rat small intestine. Drug Metab Pharmacokinet 17:546-553.
62. Iwasaki, K., Murayama, N., Koizumi, R., Uno, Y., Yamazaki, H. (2010). Comparison of cytochrome P450 3A enzymes in cynomolgus monkeys and humans. Drug Metab Pharmacokinet 25:388-391.
63. Iwasaki, K., Uno, Y. (2009). Cynomolgus monkey CYPs: comparison with human CYPs. Xenobiotica 39:578-581.
64. Jäger, W., Correia, M. A., Bornheim, L. M., Mahnke, A., Hanstein, W. G., Xue, L., et al. (1999). Ethynylestradiol-mediated induction of hepatic CYP3A9 in female rats: implication for cyclosporine metabolism. Drug Metab Dispos 27:1505-1511.
65. Jeong, E. J., Liu, Y., Lin, H., Hu, M. (2005). Species-and disposition model-dependent metabolism of raloxifene in gut and liver: role of UGT1A10. Drug Metab Dispos 33:785-794. (Pubitemid 40686632)
66. Jetter, A., Kinzig-Schippers, M., Walchner-Bonjean, M., Hering, U., Bulitta, J., Schreiner, P., et al. (2002). Efects of grapefruit juice on the pharmacokinetics of sildenafl. Clin Pharmacol Ter 71:21-29. (Pubitemid 34124035)
67. Jin, M., Shimada, T., Yokogawa, K., Nomura, M., Kato, Y., Tsuji, A., et al. (2006). Contributions of intestinal P-glycoprotein and CYP3A to oral bioavailability of cyclosporin A in mice treated with or without dexamethasone. Int J Pharm 309:81-86. (Pubitemid 43129468)
68. Kaji, H., Kume, T. (2005). Regioselective glucuronidation of denopamine: marked species diferences and identifcation of human UDP-glucuronosyltransferase isoform. Drug Metab Dispos 33:403-412. (Pubitemid 40279941)
69. Kanazu, T., Okamura, N., Yamaguchi, Y., Baba, T., Koike, M. (2005). Assessment of the hepatic and intestinal frst-pass metabolism of midazolam in a CYP3A drug-drug interaction model rats. Xenobiotica 35:305-317. (Pubitemid 40868567)
70. Kanazu, T., Yamaguchi, Y., Okamura, N., Baba, T., Koike, M. (2004). Model for the drug-drug interaction responsible for CYP3A enzyme inhibition. I: Evaluation of cynomolgus monkeys as surrogates for humans. Xenobiotica 34:391-402. (Pubitemid 38901450)
71. Kato, M., Chiba, K., Hisaka, A., Ishigami, M., Kayama, M., Nizuno, N., et al. (2003). Te intestinal frst-pass metabolism of substrates of CYP3A4 and P-glycoprotein. Quantitative analysis based on information from the literature. Drug Metab Pharmacokinet 18:365-372.
72. Kato, R., Yuasa, H., Inoue, K., Iwao, T., Tanaka, K., Ooi, K., et al. (2007). Efect of lactobacillus casei on the absorption of nifedipine from rat small intestine. Drug Metab Pharmacokinet 22:96-102.
73. Kemp, D. C., Fan, P. W., Stevens, J. C. (2002). Characterization of raloxifene glucuronidation in vitro: contribution of intestinal metabolism to presystemic clearance. Drug Metab Dispos 30:694-700. (Pubitemid 34579104)
74. Kolars, J. C., Awni, W. M., Merion, R. M., Watkins, P. B. (1991). First-pass metabolism of cyclosporine by the gut. Lancet 14:1488-1490.
75. Komura, H., Iwaki, M. (2008). Species diferences in in vitro and in vivo small intestinal metabolism of CYP3A substrates. J Pharm Sci 97:1775-1800.
76. Komura, H., Yasuda, M., Yoshida, N. H., Sugiyama, Y. (2002). Species diference in nisoldipine oxidation activity in the small intestine. Drug Metab Pharmacokinet 17:427-436.
77. Kotegawa, T., Laurijssens, B. E., von Moltke, L. L., Cotreau, M. M., Perlof, M. D., Venkatakrishnan, K., et al. (2002). In vitro, pharmacokinetic, and pharmacodynamic interactions of ketoconzole and midazolam in the rat. J Pharmacol Exp Ter 302:1228-1237. (Pubitemid 34920247)
78. Kuroha, M., Kayaba, H., Kishimoto, S., Khalil, W. F., Shimoda, M., Kokue, E. (2002). Efect of oral ketoconazole on frst-pass efect of nifedipine after oral administration in dogs. J Pharm Sci 91:868-873. (Pubitemid 34639649)
79. Kuroiwa, Y., Yoshida, H., Ohshima, T., Shinohara, T., Ohguma, A., Kazuki, Y., et al. (2002). Te use of chromosome-based vectors for animal transgenesis. Gene Ter 9:708-712. (Pubitemid 34591471)
80. Kurosawa, S., Uchida, S., Ito, Y., Yamada, S. (2009). Efect of ursodeoxycholic acid on the pharmacokinetics of midazolam and CYP3A in the liver and intestine of rats. Xenobiotica 39:162-170.
81. Kuze, J., Mutoh, T., Takenaka, T., Morisaki, K., Nakura, H., Hanioka, N., et al. (2009). Separate evaluation of intestinal and hepatic metabolism of three benzodiazepines in rats with cannulated portal and jugular veins: comparison with the profle in non-cannulated mice. Xenobiotica 39:871-880.
82. Kyokawa, Y., Nishibe, Y., Wakabayashi, M., Harauchi, T., Maruyama, T., Baba, T., et al. (2001). Induction of intestinal cytochrome P450 (CYP3A) by rifampicin in beagle dogs. Chem Biol Interact 134:291-305. (Pubitemid 32406151)
83. Lampen, A., Christians, U., Bader, A., Hackbarth, I., Sewing, K. F. (1996a). Drug interactions and interindividual variability of ciclosporin metabolism in the small intestine. Pharmacology 52:159-168. (Pubitemid 26076283)
84. Lampen, A., Christians, U., Gonschior, A. K., Bader, A., Hackbarth, I., von Engelhardt, W., et al. (1996b). Metabolism of the macrolide immunosuppressant, tacrolimus, by the pig gut mucosa in the Ussing chamber. Br J Pharmacol 117:1730-1734. (Pubitemid 26121618)
85. Lampen, A., Zhang, Y., Hackbarth, I., Benet, L. Z., Sewing, K. F., Christians, U. (1998). Metabolism and transport of the macrolide immunosuppressant sirolimus in the small intestine. J Pharmacol Exp Ter 285:1104-1112. (Pubitemid 28277909)
86. Lee, J. I., Chaves-Gnecco, D., Amico, J. A., Kroboth, P. D., Wilson, J. W., Frye, R. F. (2002). Application of semisimultanenous midazolam administration for hepatic and intestinal cytochrome P450 3A phenotyping. Clin Pharmacol Ter 72:718-728. (Pubitemid 36021011)
87. Lee, Y. H., Perry, B. A., Lee, H. S., Kunta, J. R., Sutyak, J. P., Sinko, P. J. (2001). Diferentiation of gut and hepatic frst-pass efect of drugs: 1. Studies of verapamil in ported dogs. Pharm Res 18:1721-1728. (Pubitemid 34020428)
88. Lin, Y. S., Dowling, A. L., Quigley, S. D., Farin, F. M., Zhang, J., Lamba, J., et al. (2002). Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism. Mol Pharmacol 62:162-172. (Pubitemid 34680528)
89. Lindstrom, T. D., Whitaker, N. G., Whitaker, G. W. (1984). Disposition and metabolism of a new benzothiophene antiestrogen in rats, dogs, and monkeys. Xenobiotica 14:841-847. (Pubitemid 15180639)
90. Liu, Z., Hu, M. (2007). Natural polyphenol disposition via coupled metabolic pathways. Expert Opin Drug Metab Toxicol 3:389-406. (Pubitemid 47316031)
91. Loureiro, A. I., Bonifácio, M. J., Fernandes-Lopes, C., Almeida, L., Wright, L. C., Soares-Da-Silva, P. (2006). Human metabolism of nebicapone (BIA 3-202), a novel catechol-O-methyltransferase inhibitor: characterization of in vitro glucuronidation. Drug Metab Dispos 34:1856-1862. (Pubitemid 44771713)
92. Lown, K. S., Ghosh, M., Watkins, P. B. (1998). Sequences of intestinal and hepatic cytochrome P450 3A4 cDNAs are identical. Drug Metab Dispos 26:185-187. (Pubitemid 28104088)
93. Mackenzie, P. I., Bock, K. W., Burchell, B., Guillemette, C., Ikushiro, S., Iyanagi, T., et al. (2005). Nomenclature update for the mammalian UDP glycosyltransferase (UGT) gene superfamily. Pharmacogenet Genomics 15:677-685. (Pubitemid 41345319)
94. Martignoni, M., Groothuis, G., de Kanter, R. (2006). Comparison of mouse and rat cytochrome P450-mediated metabolism in liver and intestine. Drug Metab Dispos 34:1047-1054. (Pubitemid 43763764)
95. Masica, A. L., Mayo, G., Wilkinson, G. R. (2004). In vivo comparisons of constitutive cytochrome P450 3A activity assessed by alprazolam, triazolam, and midazolam. Clin Pharmacol Ter 76:341-349. (Pubitemid 39313124)
96. Matsubara, T., Kim, H. J., Miyata, M., Shimada, M., Nagata, K., Yamazoe, Y. (2004). Isolation and characterization of a new major intestinal CYP3A form, CYP3A62, in the rat. J Pharmacol Exp Ter 309:1282-1290. (Pubitemid 38669720)
97. Mazoit, J. X., Sandouk, P., Scherrmann, J. M., Roche, A. (1990). Extrahepatic metabolism of morphine occurs in humans. Clin Pharmacol Ter 48:613-618.
98. Mealey, K. L., Jabbes, M., Spencer, E., Akey, J. M. (2008). Diferential expression of CYP3A12 and CYP3A26 mRNAs in canine liver and intestine. Xenobiotica 38:1305-1312.
99. Miles, K. K., Kessler, F. K., Smith, P. C., Ritter, J. K. (2006). Characterization of rat intestinal microsomal UDP-glucuronosyltransferase activity toward mycophenolic acid. Drug Metab Dispos 34:1632-1639. (Pubitemid 44285406)
100. Miners, J. O., Mackenzie, P. I., Knights, K. M. (2010). Te prediction of drug-glucuronidation parameters in humans: UDP-glucuronosyltransferase enzyme-selective substrate and inhibitor probes for reaction phenotyping and in vitro-in vivo extrapolation of drug clearance and drug-drug interaction potential. Drug Metab Rev 42:196-208.
101. Mistry, M., Houston, J. B. (1987). Glucuronidation in vitro and in vivo. Comparison of intestinal and hepatic conjugation of morphine, naloxone, and buprenorphine. Drug Metab Dispos 15:710-717. (Pubitemid 18004628)
102. Mizuma, T. (2009). Intestinal glucuronidation metabolism may have a greater impact on oral bioavailability than hepatic glucuronidation metabolism in humans: a study with raloxifene, substrate for UGT1A1, 1A8, 1A9, and 1A10. Int J Pharm 378:140-141.
103. Muirhead, G. J., Rance, D. J., Walker, D. K., Wastall, P. (2002). Comparative human pharmacokinetics and metabolism of single-dose oral and intravenous sildenafl. Br J Clin Pharmacol 53:13-S20S
104. Murai, T., Samata, N., Iwabuchi, H., Ikeda, T. (2006). Human UDP-glucuronosyltransferase, UGT1A8, glucruonidates dihydro-testosterone to a monoglucuronide and further to a structurally novel diglucuronide. Drug Metab Dispos 34:1102-1108.
105. Murakami, T., Nakanishi, M., Yoshimori, T., Okamura, N., Norikura, R., Mizojiri, K. (2003). Separate assessment of intestinal and hepatic frst-pass efects using a rat model with double cannulation of the portal and jugular veins. Drug Metab Pharmacokinet 18:252-260.
106. Muzeeb, S., Basha, S. J., Shashikumar, D., Mullangi, R., Srinivas, N. R. (2006). Glucuronidation of DRF-6574, hydroxyl metabolite of DRF-4367 (a novel COX-2 inhibitor) by pooled human liver, intestinal microsomes, and recombinant human UDP-glucuronosyltransferases (UGT): role of UGT1A1, 1A3, and 1A8. Eur J Drug Metab Pharmacokinet 31:299-309.
107. Nakamura, A., Nakajima, M., Yamanaka, H., Fujiwara, R., Yokoi, T. (2008). Expression of UGT1A and UGT2B mRNA in human normal tissues and various cell lines. Drug Metab Dispos 36:1461-1464.
108. Nakanishi, Y., Matsushita, A., Matsuno, K., Iwasaki, K., Utoh, M., Nakamura, C., et al. (2010). Regional distribution of cytochrome P450 mRNA expression in the liver and small intestine of cynomolgus monkeys. Drug Metab Pharmacokinet 25:290-297.
109. Nishikawa, M., Ariyoshi, N., Kotani, A., Ishii, I., Nakamura, H., Nakasa, H., et al. (2004). Efects of continuous ingestion of green tea or grape seed extracts on the pharmacokinetics of midazolam. Drug Metab Pharmacokinet 19:280-289.
110. Nishimura, T., Amano, N., Kubo, Y., Ono, M., Kato, Y., Fujita, H., et al. (2007). Asymmetric intestinal frst-pass metabolism causes minimal oral bioavailability of midazolam in cynomolgus monkey. Drug Metab Dispos 35:1275-1284. (Pubitemid 47121767)
111. Nishimura, M., Koeda, A., Morikawa, H., Satoh, T., Narimatsu, S., Naito, S. (2009). Tissue-specifc mRNA expression profles of drug-metabolizing enzymes and transporters in the cynomolgus monkey. Drug Metab Pharmacokinet 24:139-144.
112. Nishimura, M., Yaguti, H., Yoshitsugu, H., Naito, S., Satoh, T. (2003). Tissue distribution of mRNA expression of human cytochrome P450 isoforms assessed by high-sensitivity real-time reverse transcription PCR. Yakugaku Zasshi 123:369-375. (Pubitemid 41327466)
113. Nishimuta, H., Sato, K., Mizuki, Y., Yabuki, M., Komuro, S. (2010). Prediction of the intestinal frst-pass metabolism of CYP3 substrates in humans using cynomolgus monkeys. Drug Metab Dispos 38:1967-1975.
114. Ogasawara, A., Kume, T., Kazama, E. (2007). Efect of oral ketoconazole on intestinal frst-pass efect of midazolam and fexofenadine in cynomolgus monkeys. Drug Metab Dispos 35:410-418. (Pubitemid 46333904)
115. Ohno, S., Nakajin, S. (2009). Determination of mRNA expression of human UDP-glucuronosyltransferases and application for localization in various human tissues by real-time reverse transcriptase-polymerase chain reaction. Drug Metab Dispos 37:32-40.
116. Ohtsuka, T., Yoshikawa, T., Kozakai, K., Tsuneto, Y., Uno, Y., Utho, M., et al. (2010). Alprazolam as an in vivo probe for studing induction of CYP3A in cynomolgus monkeys. Drug Metab Dispos 38:1806-1813.
117. Osborne, R., Joel, S., Trew, D., Slevin, M. (1990). Morphine and metabolite behavior after diferent routes of morphine administration: demonstration of the importance of the active metabolite morphine-6-glucuronide. Cline Pharmacol Ter 47:12-19. (Pubitemid 20041204)
118. Oshimura, M., Katoh, M. (2008). Transfer of human artifcial chromosome vectors into stem cells. Reprod Biomed Online 16:57-69. (Pubitemid 351187374)
119. Paine, M. F., Hart, H. L., Ludington, S. S., Haining, R. L., Rettie, A. E., Zeldin, D. C. (2006). Te human intestinal cytochrome P450 "pie". Drug Metab Dispos 34:880-886.
120. Paine, M. F., Khalighi, M., Fisher, J. M., Shen, D. D., Kunze, K. L., Marsh, C. L., et al. (1997). Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. J Pharmacol Exp Ter 283:1552-1562. (Pubitemid 28016533)
121. Paine, M. F., Shen, D. D., Kunze, K. L., Perkins, J. D., Marsh, C. L., McVicar, J. P., et al. (1996). First-pass metabolism of midazolam by the human intestine. Clin Pharmacol Ter 60:14-24. (Pubitemid 26279216)
122. Patel, J. P., Korashy, H. M., EI-Kadi, A. O., Brocks, D. R. (2010). Efect of bile and lipids on the stereoselective metabolism of halofantrine by rat everted-intestinal sacs. Chirality 22:275-283.
123. Prueksaritanont, T., Gorham, L. M., Hochman, J. H., Tran, L. O., Vyas, K. P. (1996). Comparative studies of drug-metabolizing enzymes in dog, monkey, and human small intestines, and in Caco-2 cells. Drug Metab Dispos 24:634-642. (Pubitemid 26170714)
124. Ritter, J. K. (2007). Intestinal UGTs as potential modifers of pharmacokinetics and biological responses to drugs and xenobiotics. Exp Opin Drug Toxicol 3:93-107. (Pubitemid 47307457)
125. Sakuda, S., Akabane, T., Teramura, T. (2006). Marked species diferences in the bioavailability of midazolam in cynomolgus monkeys and humans. Xenobiotica 36:331-340.
126. Sandström, R., Knutson, T. W., Knutson, L., Jansson, B., Lennernäs, H. (1999). Te efect of ketoconazole on the jejunal permeability and CYP3A metabolism of (R/S)-verapamil in humans. Br J Clin Pharmacol 48:180-189. (Pubitemid 29349453)
127. Schmider, J., Greenblatt, D. J., von Moltke, L. L., Harmatz, J. S., Shader, R. I. (1995). N-demethylation of amitriptyline in vitro: role of cytochrome P-450 3A (CYP3A) isforms and efect of metabolic inhibitors. J Pharmacol Exp Ter 275:592-597. (Pubitemid 26025547)
128. Shelby, M. K., Cherrington, N. J., Vansell, N. R., Klaassen, C. D. (2003). Tissue mRNA expression of the rat UDP-glucuronosyltransferase gene family. Drug Metab Dispos 31:326-333. (Pubitemid 36249688)
129. Shimada, T., Yamazaki, H., Mimura, M., Inui, Y., Guengerich, F. P. (1994). Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens, and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ter 270:414-423. (Pubitemid 24229655)
130. Shin, H. S., Bae, S. K., Lee, M. G. (2006). Pharmacokinetics of sildenafl after intravenous and oral administration in rats: hepatic and intestinal frst-pass efects. Int J Pharm 320:64-70. (Pubitemid 44128707)
131. Shiratani, H., Katoh, M., Nakajima, M., Yokoi, T. (2008). Species diferences in UDP-glucuronosyltransferase activities in mice and rats. Drug Metab Dispos 36:1745-1752.
132. Silberberg, M., Morand, C., Mathevon, T., Besson, C., Manach, C., Scalbert, A., et al. (2006). Te bioavailability of polyphenols is highly governed by the capacity of the intestine and of the liver to secrete conjugated metabolites. Eur J Nutr 45:88-96. (Pubitemid 43345201)
133. Soars, M. G., Burchell, B., Riley, R. J. (2002). In vitro analysis of human drug glucuronidation and prediction of in vivo metabolic clearance. J Pharmacol Exp Ter 301:382-390. (Pubitemid 34250317)
134. Strassburg, C. P., Kneip, S., Topp, J., Obermayer-Straub, P., Barut, A., Tukey, R. H., et al. (2000). Polymorphic gene regulation and interindividual variation of UDP-glucuronosyltransferase activity in human small intestine. J Biol Chem 275:36164-36171.
135. Strelevitz, T. J., Foti, R. S., Fisher, M. B. (2006). In vivo use of the P450 inactivator 1-aminobenzotriazole in the rat: varied dosing route to elucidate gut and liver contributions to frst-pass and systemic clearance. J Pharm Sci 95:1334-1341. (Pubitemid 43874447)
136. Tachibana, T., Kato, M., Takano, J., Sugiyama, Y. (2010). Predicting drug-drug interactions involving the inhibition of intestinal CYP3A and P-glycoprotein. Curr Drug Metab 11:762-777.
137. Takahashi, M., Washio, T., Suzuki, N., Igeta, K, Yamashita, S. (2009). Te species diferences of intestinal drug absorption and frst-pass metabolism between cynomolgus monkeys and humans. J Pharm Sci 98:4343-4353.
138. Takanaga, H., Ohnishi, A., Murakami, H., Matsuo, H., Higuchi, S., Urae, A., et al. (2000). Relationship between time after intake of grapefruit juice
139. Takara, K., Ohnishi, N., Horibe, S., Yokoyama, T. (2003). Expression profles of drug-metabolizing enzyme CYP3A and drug efux transporter multidrug resistance 1 subfamily mRNAs in rat small intestine. Drug Metab Dispos 31:1235-1239. (Pubitemid 37152974)
140. Takemoto, K., Yamazaki, H., Tanaka, Y., Nakajima, M., Yokoi, T. (2003). Catalytic activities of cytochrome P450 enzymes and UDP- glucuronosyltransfereases involved in drug metabolism in rat everted sacs and intestinal microsomes. Xenobiotica 33:43-55. (Pubitemid 36071762)
141. Tang, L., Singh, R., Liu, Z., Hu, M. (2009). Structure and concentration changes afect characterization of UGT isoform-specifc metabolism of isofavones. Mol Pharm 6:1466-1482.
142. Tummel, K. E., O'Shea, D., Paine, M. F., Shen, D. D., Kunze, K. L., Perkins, J. D., et al. (1996). Oral frst-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clin Pharmacol Ter 59:491-502. (Pubitemid 26193889)
143. Tsunoda, S. M., Velez, R. L., von Moltke, L. L., Greenblatt, D. J. (1999). Diferentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: efect of ketoconazole. Clin Pharmacol Ter 66:461-471.
144. Tsuruta, S., Nakamura, K., Arimori, K., Nakano, M. (1997). Inhibition of nifedipine metabolism in dogs by erythromycin: diference between the gut wall and the liver. J Pharm Pharmacol 49:1205-1210. (Pubitemid 28022219)
145. Uno, Y., Matsushita, A., Osada, N., Uehara, S., Kohara, S., Nagata, R., et al. (2010). Genetic variants of CYP3A4 and CYP3A5 in cynomolgus and rhesus macaques. Drug Metab Dispos 38:209-214.
146. van de Kerkhof, E. G., Ungell, A. L., Sjöberg, Å,. K., de Jager, M. H., Hilgendorf, C., de Graaf, I. A., et al. (2006). Innovative methods to study human intestinal drug metabolism in vitro: precision-cut slices compared with Ussing chamber preparations. Drug Metab Dispos 34:1893-1902. (Pubitemid 44771719)
147. van Herwaarden, A. E., van Waterschoot, R. A., Schinkel, A. H. (2009). How important is intestinal cytochrome P450 3A metabolism? Trends Pharmacol Sci 30:223-227.
148. van Herwaarden, A. E., Wagenaar, E., van der Kruijssen, C. M., van Waterschoot, R. A., Smit, J. W., et al. (2007). Knockout of cytochrome P450 3A yields new mouse models for understanding xenobiotic metabolism. J Clin Invest 117:3583-3592. (Pubitemid 350097013)
149. van Waterschoot, R. A., Rooswinkel, R. W., Sparidans, R. W., van Herwaarden, A. E., Beijnen, J. H., Schinke, A. H. (2009). Inhibition and simulation of intestinal and hepatic CYP3A activity: studies in humanized CYP3A4 transgenic mice using triazolam. Drug Metab Dispos 37:2305-2313.
150. von Richter, O., Burk, O., Fromm, M. F., Ton, K. P., Eichelbaum, M., Kivistö, K. T. (2004). Cytochrome P450 3A4 and P-glycoprotein expression in human small intestinal enterocytes and hepatocytes: a comparative analysis in paired tissue specimens. Clin Pharmacol Ter 75:172-183. (Pubitemid 38314866)
151. von Richter, O., Greiner, B., Fromm, M. F., Fraser, R., Omari, T., Barclay, M. L., et al. (2001). Determination of in vivo absorption, metabolism, and transport of drugs by the human intestinal wall and liver with a novel perfusion technique. Clin Pharmacol Ter 70:217-227. (Pubitemid 32868485)
152. Wakui, Y., Yanagisawa, E., Ishibashi, E., Matsuzaki, Y., Takeda, S., Sasaki, H., et al. (1992). Determination of baicalin and baicalein in rat plasma by high-performance liquid chromatography wih electrochemical detection. J Chromatogr 575:131-136.
153. Watanabe, Y., Nakajima, M., Yokoi, T. (2002). Troglitazone glucuronidation in human liver and intestine microsomes: high catalytic activity of UGT1A8 and UGT1A10. Drug Metab Dispos 30:1462-1469. (Pubitemid 35397055)
154. Watkins, P. B., Wrighton, S. A., Schuetz, E. G., Molowa, D. T., Guzelian, P. S. (1987). Identifcation of glucocorticoid-inducible cytochrome P-450 in the intestinal mucosa of rats and man. J Clin Invest 80:1029-1036. (Pubitemid 18075638)
155. Wilkinson, G. R. (2005). Drug metabolism and variability among patients in drug response. N Engl J Med 352:2211-2221.
156. Williams, J. A., Hyland, R., Jones, B. C., Smith, D. A., Hurst, S., Goosen, T. C., et al. (2004). Drug-drug interactions for UDP- glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCI/AUC) ratios. Drug Metab Dispos 32:1201-1208. (Pubitemid 39410902)
157. Wojnowski, L., Kamdem, L. K. (2006). Clinical implications of CYP3A polymorphisms. Exp Opin Drug Metab Toxicol 2:171-182. (Pubitemid 46372363)
158. Yamanaka, H., Nakajima, M., Katoh, M., Yokoi, T. (2007). Glucuronidation of thyroxine in human liver, jejunum, and kidney microsomes. Drug Metab Dispos 35:1642-1648. (Pubitemid 47296059)
159. Yang, J., Tucker, G. T., Rostami-Hodjegan, A. (2004). Cytochrome P450 3A expression and activity in the human small intestine. Clin Pharmacol Ter 76:391. (Pubitemid 39313131)
160. Yokomasu, A., Yano, I., Sato, E., Masuda, S., Katsura, T., Inui, K. (2008). Efect of intestinal and hepatic frst-pass extraction on the pharmacokinetics of everlimus in rats. Drug Metab Pharmacokinet 23:469-475.
161. Yoshisue, K., Nagayama, S., Shindo, T., Kawaguchi, Y. (2001). Efects of 5-fuorouracil on the drug-metabolizing enzymes of the small intestine and the consequent drug interaction with nifedipine in rats. J Pharmacol Exp Ter 297:1166-1175. (Pubitemid 32472518)
162. Zhang, Q. Y., Dunbar, D., Kaminsky, L. S. (2003). Characterization of mouse small intestinal cytochrome P450 expression. Drug Metab Dispos 31:1346-1351. (Pubitemid 37310323)
163. Zhang, Q. Y., Dunbar, D., Ostrowska, A., Zeisloft, S., Yang, J., Kaminsky, L. S. (1999). Characterization of human small intestinal cytochromes P-450. Drug Metab Dispos 27:804-809. (Pubitemid 29297778)
164. Zhang, Q. Y., Fang, C., Zhang, J., Dunbar, D., Kaminsky, L., Ding, X. (2009b). An intestinal epithelium-specifc cytochrome P450 (P450) reductase-knockout mouse model: direct evidence for a role of intestinal cytochrome P450s in frst-pass clearance of oral nefedipine. Drug Metab Dispos 37:651-657.
165. Zhang, Q. Y., Kaminsky, L. S., Dunbar, D., Zhang, J., Ding, X. (2007). Role of small intestinal cytochromes P450 in the bioavailability of oral nifedipine. Drug Metab Dispos 35:1617-1623. (Pubitemid 47296056)
166. Zhang, L., Lin, G., Chang, Q., Zuo, Z. (2005). Role of intestinal frst-pass metabolism of baicalein in its absorption process. Pharm Res 22:1050-1058. (Pubitemid 41127062)
167. Zhang, L., Lin, G., Zuo, Z. (2006). Involvement of UDP- glucuronosyltransferases in the extensive liver and intestinal frst-pass metabolism of favonoid baicalein. Pharm Res 24:81-89. (Pubitemid 44902573)
168. Zhang, QY, Wikof, J, Dunbar, D, Kaminsky, L. (1996). Characterization of rat small intestinal cytochrome P450 composition and inducibility. Drug Metab Dispos 24:322-328. (Pubitemid 26087086)
169. Zhang, H., Wu, X., Naraharisetti, S. B., Chung, F., Whittington, D., Mirfazaclian, A., et al. (2009a). Pregnancy does not increase CYP3A or P-glycoprotein activity in the non-human primate, Macaca nemestrina. J Pharmacol Exp Ter 330:586-595.
170. Zhu, Y., D'Agostino, J., Zhang, Q.-Y. (2011). Role of intestinal cytochrome P450 in modulating the bioavailability of oral lovastatin: insights from studies on the intestinal epithelium-specifc P450 reductase knockout mouse. Drug Metab Dispos 39;939-943.
171. Zuber, R., Anzenbacherová, E., Anzenbacher, P. (2002). Cytochrome P450 and experimental models of drug metabolism. J Cell Mol Med 6:189-198. (Pubitemid 44137197)